Person:
Meister, Glenna E.

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Meister

First Name

Glenna E.

Name

Meister, Glenna E.
Author's Publications: search.filters.isAuthorOfPublication.dd7e1bf8-69c0-43bd-ad77-27f4f688f562

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Targeted DNA methylation in human cells using engineered dCas9-methyltransferases
    (Nature Publishing Group UK, 2017) Xiong, Tina; Meister, Glenna E.; Workman, Rachael E.; Kato, Nathaniel C.; Spellberg, Michael J.; Turker, Fulya; Timp, Winston; Ostermeier, Marc; Novina, Carl
    Mammalian genomes exhibit complex patterns of gene expression regulated, in part, by DNA methylation. The advent of engineered DNA methyltransferases (MTases) to target DNA methylation to specific sites in the genome will accelerate many areas of biological research. However, targeted MTases require clear design rules to direct site-specific DNA methylation and minimize the unintended effects of off-target DNA methylation. Here we report a targeted MTase composed of an artificially split CpG MTase (sMTase) with one fragment fused to a catalytically-inactive Cas9 (dCas9) that directs the functional assembly of sMTase fragments at the targeted CpG site. We precisely map RNA-programmed DNA methylation to targeted CpG sites as a function of distance and orientation from the protospacer adjacent motif (PAM). Expression of the dCas9-sMTase in mammalian cells led to predictable and efficient (up to ~70%) DNA methylation at targeted sites. Multiplexing sgRNAs enabled targeting methylation to multiple sites in a single promoter and to multiple sites in multiple promoters. This programmable de novo MTase tool might be used for studying mechanisms of initiation, spreading and inheritance of DNA methylation, and for therapeutic gene silencing.
  • Thumbnail Image
    Publication
    An Engineered Calmodulin-Based Allosteric Switch for Peptide Biosensing
    (Wiley Blackwell (John Wiley & Sons), 2013) Meister, Glenna E.; Joshi, Neel
    This work describes the development of a new platform for allosteric protein engineering that takes advantage of the ability of calmodulin to change conformation upon binding to peptide and protein ligands. The switch we have developed consists of a fusion protein in which calmodulin is genetically inserted into the sequence of TEM1 β-lactamase. In this approach, calmodulin acts as the input domain, whose ligand-dependent conformational changes control the activity of the β-lactamase output domain. The new allosteric enzyme exhibits up to 120 times higher catalytic activity in the activated (peptide bound) state compared to the inactive (no peptide bound) state in vitro. Activation of the enzyme is ligand-dependent-peptides with higher affinities for wild-type calmodulin exhibit increased switch activity. Calmodulin's ability to "turn on" the activity of β-lactamase makes this a potentially valuable scaffold for the directed evolution of highly specific biosensors for detecting toxins and other clinically relevant biomarkers.